Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07422337 · ClinicalTrials.gov registry record
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
A clinical trial of B-cell Acute Lymphoblastic Leukemia and B-cell Acute Lymphoblastic Leukemia (B-ALL), sponsored by Arkansas Children's Hospital Research Institute.
- Recruiting
- Registry status
- 300
- Enrollment target
- 2
- Study locations
NCT07422337 is a study of B-cell Acute Lymphoblastic Leukemia and B-cell Acute Lymphoblastic Leukemia (B-ALL) that is actively recruiting participants, run by Arkansas Children's Hospital Research Institute. The registered enrollment target is 300 participants, above the 75-participant average among 21 other B-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (300% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT07422337, a study of B-cell Acute Lymphoblastic Leukemia and B-cell Acute Lymphoblastic Leukemia (B-ALL), is actively recruiting participants, sponsored by Arkansas Children's Hospital Research Institute.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are: * Evaluate the persistence of protective immunity to routine childhood vaccinations in participants with B-ALL/Ly who have received blinatumomab. * To determine whether revaccination in participants with non-protective titers leads to restored humoral immunity. Researchers will compare results from participants who have received immunotherapy to those who have not received immunotherapy to see if immunotherapy versus other chemotherapeutic drugs adversely affect the protective immunity acquired through vaccination.
Conditions Studied
Study Locations (2)
Arkansas
- Arkansas Children's - Little Rock
- Arkansas Children's Northwest - Springdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-01-13 |
| Est. Completion | 2029-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07422337
The ClinicalTrials.gov registry entry for NCT07422337 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 75-participant average among 21 other B-cell Acute Lymphoblastic Leukemia trials with a reported enrollment target (300% higher). The listed sponsor is Arkansas Children's Hospital Research Institute, which has 97 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with B-cell Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 0 interventions.
NCT07422337 reports 2 study locations spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT07422337 about?
NCT07422337 is a clinical study titled "A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab". The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are: * Evaluate the persistence of protective immunity to routine child...
What is the current status of trial NCT07422337?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2026-01-13. Estimated completion is 2029-01.
What conditions does trial NCT07422337 study?
This clinical trial studies the following conditions: B-cell Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia (B-ALL), B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Leukemia, B-Cell ALL.
Who is sponsoring clinical trial NCT07422337?
This trial is sponsored by Arkansas Children's Hospital Research Institute, which has 97 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07422337 being conducted?
This trial has 2 study locations across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
RECRUITING · Phase 1
-
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
RECRUITING · Phase 1
-
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
RECRUITING · Phase 1
-
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
RECRUITING · Phase 2
Explore more on PlainTrial
B-cell Acute Lymphoblastic Leukemia
All registered trials for this condition
B-cell Acute Lymphoblastic Leukemia (B-ALL)
All registered trials for this condition
Arkansas
All trials with a study site in Arkansas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.